Revolution Medicines (United States)

company in Redwood City, United States

RVMD Nasdaq ISIN US76155X1000 SEC CIK 1628171 LEI 549300JU3X0LBCQ65892
Follow Revolution Medicines (United States) Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Revenue, last quarter $197.6M
Net income −$407.5M −33.5% vs same quarter last year
EPS, diluted −$1.90 −18% vs same quarter last year
Operating cash flow −$415.7M −100.5% vs same quarter last year
Revenue by quarter
$0
$0
$0
$197.6M
Q4 24 Q3 25 Q4 25 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income9 fiscal years
  • Revenue
  • Net income
−$1.5B−$1B−$500M$0$500MFY17FY18FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearRevenueNet income
FY25$0−$1.1B
FY24$0−$600M
FY23$11.6M−$436M
FY22$35.4M−$249M
FY21$29.4M−$187M
FY20$43M−$108.2M
FY19$50M−$47.7M
FY18$20.2M−$41.8M
FY17--
MarginsShare of revenue
  • Operating margin
  • Net margin
−6000%−4000%−2000%0%FY17FY18FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearOperating marginNet margin
FY25--
FY24--
FY23−4207.1%−3765.1%
FY22−730%−703.8%
FY21−639.7%−636.3%
FY20−257.5%−251.6%
FY19−108.2%−95.2%
FY18−200%−207.2%
FY17--
Free cash flowOperating cash flow minus capital expenditure
−$1B−$750M−$500M−$250M$0FY17FY18FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearFree cash flow
FY25−$913.7M
FY24−$567.7M
FY23−$358.3M
FY22−$235.2M
FY21−$153.7M
FY20−$103M
FY19−$52.2M
FY18−$286K
FY17-
Net margin vs the sectorMedian of Healthcare companies filing with the SEC
  • Revolution Medicines (United States)
  • Healthcare median
−4000%−3000%−2000%−1000%0%FY17FY18FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearRevolution Medicines (United States)Healthcare median
FY25-−30.6%
FY24-−47%
FY23−3765.1%−58%
FY22−703.8%−80.4%
FY21−636.3%−71.9%
FY20−251.6%−62.2%
FY19−95.2%−46.3%
FY18−207.2%−49.6%
FY17-−45.9%